All In Biotech

NDA 020372 · Medi-Physics

Myoview

Technetium Tc-99m Tetrofosmin Kit · Injection

Novel

Last checked: Nov 19, 2026Latest source record: Dec 6, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Feb 9, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

700

170 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 10, 2024.

MYOVIEW is a kit for the preparation of technetium Tc99m tetrofosmin for injection. Technetium Tc99m tetrofosmin injection is a radioactive diagnostic agent indicated for the following: Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease ( 1.1 ) Assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease ( 1.2 ) 1.1 Myocardial Perfusion Imaging Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease. 1.2 Ventricular Function Imaging MYOVIEW is indicated for assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease.

Mechanism: Technetium (99mTc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. After intravenous injection, it is distributed within the myocardium according to myocardial perfusion and viability.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2003 Supplement 13 · Efficacy ReviewLetterLabel
  • Nov 23, 2001 Supplement 3 · Efficacy LetterReviewLabel
  • Feb 9, 1996 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • MYOVIEW · TECHNETIUM TC-99M TETROFOSMIN KIT N/A · INJECTABLE, INJECTION · Prescription
  • MYOVIEW 30ML · TECHNETIUM TC-99M TETROFOSMIN KIT N/A · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Tetrofosmin Kit" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event409
  • radioisotope scan abnormal274
  • drug ineffective152
  • product quality issue29
  • dizziness21
  • headache21
  • nausea20
  • hypersensitivity16
  • scan myocardial perfusion abnormal16
  • urticaria16
  • vomiting16
  • dyspnoea15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20055
20065
20075
20089
20096
20109
20117
20126
20138
201417
201520
201635
201737
201836
201983
202091
202157
202238
202329
202428
202559
2026106

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Medi-Physics · Also marketed as Myoview 30ml

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.